BURLINGTON, Mass., Nov. 15, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that the type 2 diabetes market in Mexico will grow to $1.22 billion in 2014. Drivers of this growth include increasing prevalent population, expanding medical insurance coverage as well as the launch and use of new drugs in the market.

"Mexico now has the largest type 2 diabetes population in the world behind the United States, China, Japan and India," said Decision Resources Analyst Yannick Maneuf, Ph.D. "As the population ages, the size of Mexico's prevalent type 2 diabetes population will continue to grow. We also expect the diagnosed rate of type 2 diabetes will continue to increase as the Mexican government actively promotes early diagnosis of diabetes."

The new Emerging Markets report entitled Type 2 Diabetes in Mexico also finds that fixed-dose combination therapies constitute the largest drug-class sales with $289 million in sales in 2009 and $332 million expected in 2014. This is due to the uptake of new combinations, such as metformin plus sitagliptin (Merck's Janumet) and metformin plus pioglitazone (Rimsa's Diabamet and Eli Lilly's Competact). Surveyed physicians indicate that metformin and fixed-dosed combinations containing metformin will continue to be the most commonly used agents in Mexico through 2014.

"While metformin continues to be the most widely prescribed oral antidiabetic agent in Mexico, physicians now have more choices for their second- or third-line therapies with newly launched agents coming to market. Our primary research reveals that endocrinologists expect to use these agents more frequently in the next five years despite their high costs," added Dr. Maneuf.

The new report features extensive primary research of Mexican endocrinologists and epidemiology data.

About Emerging Markets Reports

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources

Decision Resources, Inc.

Lisa Osgood

Christopher Comfort





SOURCE Decision Resources

Driven by the Uptake of Several Emerging Agents, the MRSA Drug Market Will Increase From $631 Million in 2009 to $752 Million in 2019

View Now